High‐field magnetic resonance imaging of the response of human prostate cancer to Pc 4‐based photodynamic therapy in an animal model
- 25 October 2007
- journal article
- case report
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 39 (9) , 723-730
- https://doi.org/10.1002/lsm.20576
Abstract
Introduction: High‐field magnetic resonance imaging (MRI) is an emerging technique that provides a powerful, non‐invasive tool for in vivo studies of cancer therapy in animal models. Photodynamic therapy (PDT) is a relatively new treatment modality for prostate cancer, the second leading cause of cancer mortality in American males. The goal of this study was to evaluate the response of human prostate tumor cells growing as xenografts in athymic nude mice to Pc 4‐sensitized PDT.Materials and Methods: PC‐3, a cell line derived from a human prostate malignant tumor, was injected intradermally on the back flanks of athymic nude mice. Two tumors were initiated on each mouse. One was treated and the other served as the control. A second‐generation photosensitizing drug Pc 4 (0.6 mg/kg body weight) was delivered to each animal by tail vein injection 48 hours before laser illumination (672 nm, 100 mW/cm2, 150 J/cm2). A dedicated high‐field (9.4 T) small‐animal MR scanner was used for image acquisitions. A multi‐slice multi‐echo (MSME) technique, permitting noninvasive in vivo assessment of potential therapeutic effects, was used to measure the T2 values and tumor volumes. Animals were scanned immediately before and after PDT and 24 hours after PDT. T2 values were computed and analyzed for the tumor regions.Results: For the treated tumors, the T2 values significantly increased (PP = 0.53) between the pre‐PDT (52.5±6.1 milliseconds) and 24‐hour post‐PDT (54.3±6.4 milliseconds) values. Histologic analysis showed that PDT‐treated tumors demonstrated necrosis and inflammation that was not seen in the control.Discussion: Changes in tumor T2 values measured by multi‐slice multi‐echo MR imaging provide an assay that could be useful for clinical monitoring of photodynamic therapy of prostate tumors. Lesers Surg. Med. 39:723–730, 2007.Keywords
This publication has 39 references indexed in Scilit:
- Photodynamic therapy and anti-tumour immunityNature Reviews Cancer, 2006
- Magnetic resonance imaging correlated with the histopathological effect of Pd‐bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate glandLasers in Surgery and Medicine, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapyBJU International, 2005
- Optical Properties of Human Prostate at 732 nm Measured In Vivo During Motexafin Lutetium–mediated Photodynamic Therapy¶Photochemistry and Photobiology, 2005
- Transperinealin vivofluence-rate dosimetry in the canine prostate during SnET2-mediated PDTPhysics in Medicine & Biology, 2004
- Photodynamic Therapy of Prostate Cancer by Means of 5-Aminolevulinic Acid-Induced Protoporphyrin IX – In vivo Experiments on the Dunning Rat Tumor ModelUrologia Internationalis, 2004
- Optical Properties of Human Prostate at 732 nm Measured In Vivo during Motexafin Lutetium-Mediated Photodynamic TherapyPhotochemistry and Photobiology, 2004
- IN VIVO 31P NMR STUDY OF COMBINED HYPERTHERMIA and PHOTODYNAMIC THERAPIES OF MAMMARY CARCINOMA IN THE MOUSEPhotochemistry and Photobiology, 1991
- 31P-NMR spectroscopy demonstrates decreased ATP levels in vivo as an early response to photodynamic therapyBiochemical and Biophysical Research Communications, 1986